Investor Jordi Visser argues Eli Lilly's 150 years of proprietary metabolic disease data, AI infrastructure, and GLP-1 drugs like Mounjaro and Zepbound could make it the world's largest company within five years. The market still prices Lilly as a pharma stock, not an AI-powered drug discovery platform.
Tap to vote and see what everyone thinks.
SpaceX IPO: FOMO Danger for Investors in 2026
Summary by ByteBrief